ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome

Bibliography

• Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005;4:465-75
   PubMed Web of Science ®Google Scholar
• Revised IRLSSG Diagnostic Criteria for RLS. 2012. Available from: http://irlssg.org/diagnostic-criteria/ [Last accessed 10 June 2014]
   Google Scholar
• Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61-5
   PubMed Web of Science ®Google Scholar
• Allen R, Walters A, Montplaisir J, et al. Restless legs syndrome prevalence and impact, REST general population study. Arch Intern Med 2005;165:1286-92
   PubMed Web of Science ®Google Scholar
• Pearson VE, Allen RP, Dean T, et al. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med 2006;7:25-30
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Shahar E, Sharief I, Gottlieb DJ. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008;70:35-42
   PubMed Web of Science ®Google Scholar
• Merlino G, Valente M, Serafini A, Gigli GL. Restless legs syndrome: diagnosis, epidemiology, classification and consequences. Neurol Sci 2007;28(Suppl 1):37-46
   Web of Science ®Google Scholar
• Winkelmann J, Schormair B, Lichtner P, et al. Genome-wide association study of RLS identifies common variants in three genomic regions. Nat Genet 2007;39:1000-6
   PubMed Web of Science ®Google Scholar
• Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698-700
   PubMed Web of Science ®Google Scholar
• Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med 2004;5:309-15
   PubMed Web of Science ®Google Scholar
• Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep 2007;30:866-71
   PubMed Web of Science ®Google Scholar
• Manconi M, Ferini-Strambi L, Filippi M, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 2008;31:944-52
   PubMed Web of Science ®Google Scholar
• Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology 2004;63:1065-9
   PubMed Web of Science ®Google Scholar
• O’Keeffe ST. Secondary causes of restless legs syndrome in older people. Age Ageing 2005;34:349-52
   PubMed Web of Science ®Google Scholar
• Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord 2000;15:154-8
   PubMed Web of Science ®Google Scholar
• Hening W. The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization. Clin Neurophysiol 2004;115:1965-74
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol 2010;6:337-46
   PubMed Web of Science ®Google Scholar
• Merlino G, Serafini A, Robiony F, et al. Clinical experience with pramipexole in the treatment of restless legs syndrome. Expert Opin Drug Metab Toxicol 2008;4:225-35
   PubMed Web of Science ®Google Scholar
• Zintzaras E, Kitsios GD, Papathanasiou AA, et al. Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis. Clin Ther 2010;32:221-37
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Allen RP, Kohnen R, et al. International Restless Legs Syndrome Study Group. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30
   PubMed Web of Science ®Google Scholar
• Merlino G, Dolso P, Canesin R, et al. The acute effect of a low dosage of pramipexole on severe idiopathic restless legs syndrome: an open-label trial. Neuropsychobiology 2006;54:195-200
   PubMed Web of Science ®Google Scholar
• MIRAPEX: Prescribing Information. 2014. Available from: http://www.mirapexer.com [Last accessed 10 June 2014]
   Google Scholar
• Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steadystate pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997;37:520-5
   PubMed Web of Science ®Google Scholar
• Kushida CA. Ropinirole for the treatment of restless legs syndrome. Neuropsychiatr Dis Treat 2006;2:407-19
   PubMedGoogle Scholar
• Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various humas cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997;25:1211-14
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034-9
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 2002;3:23-5
   PubMed Web of Science ®Google Scholar
• Wilt TJ, MacDonald R, Ouellette J, et al. Treatment for restless legs syndrome. Agency for Healthcare Research and Quality (US), Rockville, MD; 2012
   Google Scholar
• Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011;12:440-4
   PubMed Web of Science ®Google Scholar
• Maestri M, Fulda S, Ferini-Strambi L, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med 2014;15:570-5
   PubMed Web of Science ®Google Scholar
• Coldwell MC, Boyfield I, Brown T, et al. Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2(long), D3 and D4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1999;127:1696-702
   PubMed Web of Science ®Google Scholar
• Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole Results of two randomized studies in patients with Parkinson’s disease. Clin Ther 2007;29:2654-66
   PubMed Web of Science ®Google Scholar
• Merlino G, Gigli GL. Sleep-related movement disorders. Neurol Sci 2012;33:491-513
   PubMed Web of Science ®Google Scholar
• REQUIP: Prescribing Information. 2009. Available from: http://www.requip.com [Last accessed 10 June 2014]
   Google Scholar
• Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000;39:243-54
   PubMed Web of Science ®Google Scholar
• Bloomer JC, Clarke SE, Chenery RJ. An assessment of the potential of ropinirole, a dopamine receptor agonist, to inhibit various human cytochrome P450 enzymes. Br J Pharmacol 1998;124:41
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Högl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord 2012;27:277-83
   PubMed Web of Science ®Google Scholar
• Merlino G, Serafini A, Robiony F, et al. Restless legs syndrome: differential diagnosis and management with rotigotine. Neuropsychiatr Dis Treat 2009;5:67-80
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. A promising new technology for Parkinson’s disease. Neurology 2005;65(2 Suppl 1):S6-S10
   PubMed Web of Science ®Google Scholar
• Serafini A, Lorenzut S, Gigli GL, et al. The use of rotigotine in the treatment of restless legs syndrome. Ther Adv Neurol Disord 2010;3:241-8
   PubMedGoogle Scholar
• Swart PJ, Oelen WE, Bruins AP, et al. Determination of the dopamine D2 agonist N-0923 and its major metabolites in perfused rat livers by HPLC-UV-atmospheric pressure ionization mass spectrometry. J Anal Toxicol 1994;18:71-7
   PubMed Web of Science ®Google Scholar
• Boroojerdi B, Wolff HM, Braun M, Scheller DK. Rotigotine transdermal patch for the treatment of Parkinson’s disease and restless legs syndrome. Drugs Today (Barc) 2010;46:483-505
   PubMed Web of Science ®Google Scholar
• Cawello W, Ahrweiler S, Sulowicz W, et al. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol 2012;73:46-54
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. One year open-label safety and efficacy trial with rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome. Sleep Med 2008;9:865-73
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Ferini-Strambi L, Kohnen R. Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials. Eur J Neurol 2008;15(Suppl 3):110
   Google Scholar
• Benes H, Garcia-Borreguero D, Allen R, et al. Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine - a retrospective systematic analysis of two large open-label 1-year trials. Mov Disord 2009;24(Suppl 1):438
   Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s Disease. Clin Pharmacokinet 2002;41:261-309
   PubMed Web of Science ®Google Scholar
• Katzung G. Basic & clinical pharmacology. McGraw-Hill, New York; 2007
   Google Scholar
• Wade DN, Mearrick PT, Morris JL. Active transport of L-dopa in the intestine. Nature 1973;242:463-5
   PubMed Web of Science ®Google Scholar
• Sharpless NS, Muenter MD, Tyce GM, Owen CA Jr. 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson’s disease. Clin Chim Acta 1972;37:359-69
   PubMed Web of Science ®Google Scholar
• Guilleminault C, Cetel M, Philip P. Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 1993;43:445
   PubMed Web of Science ®Google Scholar
• Comella CL. Restless legs syndrome: treatment with dopaminergic agents. Neurology 2002;58(Suppl 1):87-92
   Google Scholar
• Earley CJ, Allen RP. Augmentation of the restless legs syndrome with carbidopa-levodopa. Sleep 1996;19:801-10
   PubMed Web of Science ®Google Scholar
• Yaltho T, Ondo W. The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord 2010;3:269-75
   PubMedGoogle Scholar
• Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008;23:2267-302
   PubMed Web of Science ®Google Scholar
• Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81
   PubMed Web of Science ®Google Scholar
• Cundy KC, Annamalai T, Bu L, et al. XP13512 [(+/-)-1-([(α-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol ExpTher 2004;311:324-33
   PubMed Web of Science ®Google Scholar
• Cundy KC, Sastry S, Luo W, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol 2008;48:1378-88
   PubMed Web of Science ®Google Scholar
• Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin Ther 2012;34:201-13
   PubMed Web of Science ®Google Scholar
• LYRICA: Prescribing Information. 2013. Available from: http://www.lyrica.com [ Last accessed 10 June 2014]
   Google Scholar
• Allen RP, Chen C, Winkelman J, et al. Long-term efficacy and augmentation assessment of an alpha2delta ligand (pregabalin) compared with a dopamine agonist (pramipexole) in restless legs syndrome: results of a randomized, double-blind, placebo-controlled trial. Mov Disord 2012;27:S576
   Google Scholar
• Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49:661-9
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Radulovic LL, Posvar EL, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol 2010;50:941-50
   PubMed Web of Science ®Google Scholar
• Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003;43:277-83
   PubMed Web of Science ®Google Scholar
• Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010;11:512-19
   PubMed Web of Science ®Google Scholar
• Kim SW, Shin IS, Kim JM, et al. Bupropion may improve restless legs syndrome. A report of three cases. Clin Neuropharmacol 2005;28:298-301
   PubMed Web of Science ®Google Scholar
• Lee JJ, Erdos J, Wilkosz MF, et al. Bupropion as a possible treatment option for restless legs syndrome. Ann Pharmacother 2009;43:370-4
   PubMed Web of Science ®Google Scholar
• Bayard M, Bailey B, Acharya D, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2011;24:422-8
   PubMed Web of Science ®Google Scholar
• Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008;68:653-89
   PubMed Web of Science ®Google Scholar
• WELLBUTRIN: Prescribing Information. 2014. Available from: http://www.gsksource.com/gskprm/htdocs/documents/WELLBUTRIN-TABLETS-PI-MG.PDF [ Last accessed 10 June 2014]
   Google Scholar
• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther 2005;27:1685-95
   PubMed Web of Science ®Google Scholar
• Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997;37:737-43
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kirin Co. Ltd. Approval for manufacturing and marketing of NOURIAST_ tablets 20 mg, a novel antiparkinsonian agent. 2013. Available from: http://www.kyowa-kirin.com/news_releases/2013/e20130325_04.html. [ Last accessed 10 June 2014]
   Google Scholar
• Cieślak M, Komoszyński M, Wojtczak A. Adenosine A(2A) receptors in Parkinson’s disease treatment. Purinergic Signal 2008;4:305-12
   PubMed Web of Science ®Google Scholar
• DeCerce J, Smith LF, Gonzalez W, et al. Effectiveness and tolerability of istradefylline for the treatment of restless legs syndrome: an exploratory study in five female patients. Curr Ther Res Clin Exp 2007;68:349-59
   PubMed Web of Science ®Google Scholar
• Yang M, Soohoo D, Soelaiman S, et al. Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists. Naunyn Schmiedebergs Arch Pharmacol 2007;375:133-44
   PubMed Web of Science ®Google Scholar
• Knebel W, Rao N, Uchimura T, et al. Population pharmacokinetic-pharmacodynamic analysis of istradefylline in patients with Parkinson disease. J Clin Pharmacol 2012;52:1468-81
   PubMed Web of Science ®Google Scholar
• Rao N, Uchimura T, Mori A, et al. Evaluation of safety, tolerability, and multiple-dose pharmacokinetics of istradefylline in healthy subjects. Clin Pharmacol Ther 2008;83(Suppl 1):S99
   Google Scholar
• Rao N, Chaikin P, Dvorchik B, et al. Evaluation of the pharmacokinetic interaction of istradefylline and ketoconazole. Parkinsonism Relat Disord 2007;13(Suppl 2):S104
   Google Scholar
• Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord 2008;23:2177-85
   PubMed Web of Science ®Google Scholar
• Product monograph Targin®. 2014. Available from: http://www.purdue.ca/files/2014-08-05_Targin-pm-mktg-eng.pdf [ Last accessed 10 June 2014]
   Google Scholar
• Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol 2013;12:1141-50
   PubMed Web of Science ®Google Scholar
• Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 1996;42:747-56
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 2005;71:451-60
   PubMedGoogle Scholar
• Riley J, Eisenberg E, Müller-Schwefe G, et al. Oxycodone: a review of its use in the management of pain. Curr Med Res Opin 2008;24:175-92
   PubMed Web of Science ®Google Scholar
• Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother 2004;18:17-30
   PubMedGoogle Scholar
• AZILECT: summary of product characteristics. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000574/WC500030048.pdf [ Last accessed 10 June 2014]
   Google Scholar
• Babacan-Yildiz G, Gursoy E, Kolukisa M, Celebi A. Restless legs syndrome responsive to rasagiline treatment: a case report. Clin Neuropharmacol 2012;35:88-9
   PubMed Web of Science ®Google Scholar
• Safety and Efficacy of Rasagiline in Restless Legs Syndrome. NCT01192503. Available from: http://clinicaltrials.gov/ [ Last accessed 10 June 2014]
   Google Scholar
• Chen JJ, Ly AV. Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s disease. Am J Health Syst Pharm 2006;63:915-28
   PubMed Web of Science ®Google Scholar
• Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, secondgeneration propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 2005;45:878-94
   PubMed Web of Science ®Google Scholar
• Oldfield V, Keating GM, Perry CM. Rasagiline: a review of its use in the management of Parkinson’s disease. Drugs 2007;67:1725-47
   PubMed Web of Science ®Google Scholar
• Caccia C, Maj R, Calabresi M, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology 2006;67(Suppl 2):S18-23
   PubMed Web of Science ®Google Scholar
• Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome. Newron Pharmaceutical Spa. 2005. Available from: http://www.newron.com/user/download.aspx?FILE=OBJ00033.PDF&TIPO=FLE&NOME=SafinamideRLSPressReleaseFinal110105.pdf [Last accessed 10 June 2014]
   Google Scholar
• Marzo A, Dal Bo L, Monti NC, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res 2004;50:77-85
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Thomas A. An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs 2008;17:1115-25
   PubMed Web of Science ®Google Scholar
• Fariello RG. Safinamide. Neurotherapeutics 2007;4:110-16
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med 2013;14:675-84
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord 2011;26:2065-72
   PubMed Web of Science ®Google Scholar